Advances IN HIV/AIDS 2020

Module 1: COVID-19 and HIV Discussion

Module 2: Treatment-Naive: When and
What to Start, Rapid Initiation

Module 3: Treatment-Experienced:
ARV Regimen Simplification

Module 4: Treatment-Experienced: Two Drugs vs. Three, Unknown Resistance

Module 5: Treatment-Experienced: Three Drugs vs. Four, Resistance and HCV Co-Infection

Module 6: Weight Gain After Starting Antiretrovirals

Module 7: Adverse Event Management
after Rapid Initiation of ART

CME Information

CME INFORMATION

Course Directors:

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York

Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Program Faculty:

Brenda Appolo PA-C, MHS
Hepatology Physician Assistant
Physician Assistant /
Nurse Practitioner Manager
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

Nezam H. Afdhal, MD
Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology,
Director of Liver Center
Beth Israel Deaconess
Medical Center
Boston, Massachusetts

David E. Bernstein, MD, FACG
Chief Division of Hepatology and
Center for Liver Diseases
North Shore Long Island
Jewish Health Care System
Professor of Medicine
Hofstra North Shore-LIJ
School of Medicine
New York, New York

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease,
Professor of Medicine
University of Miami’s
School of Medicine
Miami, Florida

Wilbert Jordan, MD
Medical Director
Charles Drew Medical Center
Los Angeles, California

Alain H. Litwin, MD, MPH
Professor of Clinical Medicine
Professor of Clinical Psychiatry
& Behavioral Sciences
Albert Einstein College of Medicine
Montefior Medical Center
Bronx, New York

Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Stacey B. Trooskin, MD, PhD
Assistant Professor
Division of Infectious Diseases
and HIV Medicine
Drexel University College of Medicine
Philadelphia, Pennsylvania

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Learning Objectives

After completing this activity, participants should be better able to:

Explain the long-term consequences of untreated CHC
Implement individualized antiviral treatment based on patient characteristics using available treatment options for patients with CHC
Develop optimal approaches for managing adverse events to facilitate adherence in patients being treated for CHC
Manage drug-drug interactions and other treatment issues experienced by patients with CHC patients and patients with HCV/HIV co-infection

Release Date: May 19, 2016

Expiration Date: May 19, 2017

Estimated time to complete each Module: 30-45 minute

Media: Internet

Estimated time to complete each Module:

Thought Leader Interviews: 30-45 minutes
Case-based Panel Discussions:
Instructional Videos: